Navigation Links
BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
Date:10/27/2008

e adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commi
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... RENU 28, the world's first and only skin ... purchase in Australia and New Zealand in mid-August . , ... The tour will make stops in Brisbane on September 16, ... Sydney on the 20th, and Melbourne on the 22nd. , ... and to educate people about the new product and business ...
(Date:9/15/2014)... 2014 Cancer Immunotherapy Market ... T-cell Therapies is a new market research report ... three principal types of therapeutics that have become ... cancer immunotherapy (which is often called "immuno-oncology") in ... Adoptive cellular immunotherapy. , The regular use ...
(Date:9/15/2014)... developed a technique for controlling the surface tension of ... door to a new generation of reconfigurable electronic circuits, ... fact that the oxide "skin" of the metal ... a surfactant, lowering the surface tension between the metal ... liquid metal alloy of gallium and indium. In base, ...
(Date:9/15/2014)... Northeastern University has developed a novel method for ... of nanocarbon structures in carbon nanotube arrays. The ... allow the researchers to tailor the physical properties ... from electronic devices to CNT-reinforced composite materials found ... Their findings were published in the journal ...
Breaking Biology Technology:Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Researchers control surface tension to manipulate liquid metals 2Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... Pa. , Feb. 2 Fibrocell Science, ... on the development of regenerative cell therapy for aesthetic, ... Pernock , Chairman of the Board of Directors, has ... most recently served as Senior Vice President (SVP), Pharmaceuticals, ...
... , LIVERPOOL, February 2 ... Cambian healthcare Noel Tracey to lead its,expanding Community ... Noel has more than 15 years, experience of senior management ... In his previous role as,director of operations at Cambian Healthcare, ...
... ... the life of the International Space Station (ISS) to 2020 or beyond. , ... (Vocus) February 1, 2010 -- Astrogenetix is ... Station (ISS) to 2020 or beyond. , ,Thomas B. Pickens III, Chairman of Astrogenetix, Inc.:, ...
Cached Biology Technology:Fibrocell Science, Inc. Names David Pernock Chief Executive Officer 2Fibrocell Science, Inc. Names David Pernock Chief Executive Officer 3Noel Tracey to Head Up Gray Healthcare Recovery Team 2Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement 2
(Date:9/16/2014)... , Sept. 16, 2014  Cross Match ... management solutions, announced today the launch of its ... authenticate the identity of an individual using their ... Verifier Sentry rapidly reads credential documents with embedded ... by matching the biometric to a live scan ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... research has determined that a single group of microorganisms ... B12 production in the oceans, with implications for the ... B12 is an essential molecule required by most life ... relatively small group of microorganisms because it is so ... key role in maintaining the brain and nervous systems, ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
... application of biosolids (treated municipal sewage sludge) is a ... plant nutrients and organic matter. However, the presence of ... that farmland application may result in accumulation of dioxins ... food chain because several congeners of dioxins have extremely ...
... remotely piloted aircraft carrying a NASA sensor flew over ... will be used to help fight more than 300 ... for next week. The flights by NASA,s ... Scanner developed at NASA,s Ames Research Center at Moffett ...
... In one of the first studies to link ... published in the August issue of the ... serious and violent delinquencythat gain predictive precision when ... friends and school processes. Sociologists from the ...
Cached Biology News:Dioxin risk in soil and plant tissues after long-term biosolids application 2NASA responds to California wildfire emergency imaging request 2NASA responds to California wildfire emergency imaging request 3Sociological research shows combined impact of genetics, social factors on delinquency 2
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...
...
... a fast, easy to use, reproducible and ... are 15 times faster and 5 times ... 5%). ,The VoluPAC tubes enable the determination ... a cell suspension, resulting in absolute data ...
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
Biology Products: